Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement

MA Dimopoulos, AA Palumbo, M Attal, M Beksac, FE Davies, M Delforge, H Einsele, R Hajek, JL Harousseau, FL da Costa, H Ludwig, UH Mellqvist, GJ Morgan, JF San-Miguel, S Zweegman, Pieter Sonneveld

Research output: Contribution to journalArticleAcademicpeer-review

103 Citations (Scopus)


An expert panel convened to reach a consensus regarding the optimal use of lenalidomide in combination with dexamethasone (Len/Dex) in patients with relapsed or refractory multiple myeloma (RRMM). On the basis of the available evidence, the panel agreed that Len/Dex is a valid and effective treatment option for most patients with RRMM. As with other therapies, using Len/Dex at first relapse is more effective regarding response rate and durability than using it after multiple salvage therapies. Len/Dex may be beneficial regardless of patient age, disease stage and renal function, although the starting dose of lenalidomide should be adjusted for renal impairment and cytopenias. Long-term treatment until there is evidence of disease progression may be recommended at the best-tolerated doses of both lenalidomide and dexamethasone. Recommendations regarding the prevention and management of adverse events, particularly venous thromboembolism and myelo-suppression, were provided on the basis of the available evidence and practical experience of panel members. Ongoing trials will provide more insight into the effects of continuous lenalidomide-based therapy in myeloma. Leukemia (2011) 25, 749-760; doi: 10.1038/leu.2011.3; published online 4 February 2011
Original languageUndefined/Unknown
Pages (from-to)749-760
Number of pages12
Issue number5
Publication statusPublished - 2011

Research programs

  • EMC MM-02-41-03

Cite this